Will Biogen’s new Alzheimer’s drug’s burden on Medicare be big, huge, or catastrophic?
(By Rachel Cohrs and J. Emory Parker for STAT) The Food and Drug Administration’s decision to grant wide-ranging approval to
Read More
Part D/Prescription Drugs
Why Drug Price Negotiation Has Staying Power
(By Drew Altman for Kaiser Family Foundation, published June 25, 2021) The fact that prescription drugs represent just 10% of national
Read MoreMedicare spent $2.1B on discarded drugs in 2 years, study shows
(By Katie Adams for Becker’s Hospital Review) More than $2.1 billion of Medicare Part B’s spending from 2017 to 2019 went
Read MorePoint32Health challenges Aduhelm, threatens coverage for 1.1M members
(By Nick Moran for Becker’s Hospital Review) Point32Health may not cover Biogen’s new Alzheimer’s treatment, Aduhelm, for its commercial members unless
Read MoreA crucial, overlooked question on the new Alzheimer’s drug: When should patients stop taking it?
(By Megan Molteni for STAT) For families and physicians grappling with the historic approval this month of the controversial Alzheimer’s
Read More5 BCBS plans back pharmacy startup
(By Nick Moran for Becker’s Hospital Review) Five Blue Cross Blue Shield plans are funding and collaborating with Evio, a
Read MoreDrug-resistant bacteria pose a growing threat. Can new antibiotics be developed fast enough to combat them?
(By Ed Silverman for STAT) In 2016, a landmark report was issued on the global problem of antimicrobial resistance. The paper,
Read MoreAduhelm could soon represent 1% of all US healthcare spending
(By Katie Adams for Becker’s Hospital Review) Biogen’s Alzeheimer’s drug Aduhelm could single-handedly represent 1 percent of all national healthcare
Read MoreBrain cancer drug Gleostine pulled from Medicare Part D
(By Lauren Jensik for Becker’s Hospital Review) Brain cancer drug Gleostine is no longer available for coverage under Medicare Part
Read MoreMedicare’s spending on ‘ultra-expensive’ drugs increased by 1,170% in 6 years Katie Adams – 19 hours ago Print | Email
(By Katie Adams for Becker’s Hospital Review) As more drugs enter the market with five-figure annual list prices, a large
Read More